Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Beijing Lingfu Biotechnology

Request full access

A company dedicated to exploring experimental animal resources, animal model technology and innovative scientific research services

ChinaFounded 2021Food

About Beijing Lingfu Biotechnology

Beijing Lingfu Biotechnology Co., Ltd. operates as a specialized contract research organization (CRO) focused on providing experimental animal models and related scientific research services. Established in 2021 and headquartered in Beijing, China, the company has positioned itself as a key service provider for the burgeoning biomedical industry.

The company was incubated and jointly established by Beijing Saifu Pharmaceutical Research Institute Co., Ltd., Beijing Renyuan Xinsheng Biotechnology Co., Ltd., and a team of experts from the experimental animal sector. This strategic foundation provides Lingfu with a substantial knowledge base and industry network. Since its inception, the company has secured significant financial backing, reflecting investor confidence in its business model and the market's potential. It completed an angel round of nearly 50 million yuan, followed by a pre-A round of over 200 million yuan in April 2022, led by Guoshou Equity and Junlian Capital. A subsequent Series A round in December 2022 raised an additional $24.4 million, bringing its total funding to $57.1 million with investors including MSA, Puhua Capital, and China Life Investment. This capital is primarily being deployed to expand its experimental animal resource base and laboratory facilities.

Lingfu Biotechnology's core business revolves around the provision and development of large animal models for disease research, serving clients such as research institutions and hospitals. Its offerings encompass a comprehensive range of experimental animals, including beagle dogs, marmosets, cynomolgus monkeys, and miniature pigs. Beyond simply supplying animal models, the company provides a suite of value-added scientific research services. These services include animal behavior analysis, imaging, testing, foster care, and decontamination, effectively offering an integrated platform for preclinical research. The company aims to create a complete industrial chain solution, covering everything from the experimental animals themselves to sophisticated animal models and high-value research services, supporting crucial drug development processes.

Source: Dealroom company data

At a glance

Status
Operational
Open positions
None listed
Dealroom signal
18.7/100
Industry
Food
Client focus
B2B
Links
Website

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC Apr 2023 — — Sanya Yazhou Bay Venture Capital · Hainan Rongzhi Fund · SDIC Venture Capital ↗
SERIES A✓Equity / VC Dec 2022 $23M $94M Beijing Saifu Pharmaceutical Research Institute · Sanya Yazhou Bay Venture Capital · Legend Capital · MSA Capital ↗
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Beijing Lingfu Biotechnology website traffic

Latest recorded traffic for Beijing Lingfu Biotechnology is 140 monthly website visits, up 250% over the last three months.

Latest monthly visits140 3-month web change+250%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Beijing Lingfu Biotechnology in its local ecosystem

Live from Dealroom

The Beijing Lingfu Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

7 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A7 investors entered at this stage

  • Beijing Saifu Pharmaceutical Research Institute
  • Sanya Yazhou Bay Venture Capital
  • Legend Capital
  • MSA Capital
  • Puhua Capital
  • Hainan Rongzhi Fund
  • SDIC Venture Capital
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇳 China HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Beijing Lingfu Biotechnology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Beijing Lingfu Biotechnology’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.